Regulus Therapeutics Management
Management criteria checks 2/4
Regulus Therapeutics' CEO is Jay Hagan, appointed in May 2017, has a tenure of 7.5 years. total yearly compensation is $2.57M, comprised of 23.9% salary and 76.1% bonuses, including company stock and options. directly owns 0.087% of the company’s shares, worth $79.95K. The average tenure of the management team and the board of directors is 5.3 years and 7.5 years respectively.
Key information
Jay Hagan
Chief executive officer
US$2.6m
Total compensation
| CEO salary percentage | 23.9% |
| CEO tenure | 7.5yrs |
| CEO ownership | 0.09% |
| Management average tenure | 5.3yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth
Sep 28
Regulus surges 15% after Phase 1 data for kidney disease candidate
Sep 12Regulus Therapeutics GAAP loss per share narrows
Aug 11Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?
Oct 12The Read On Regulus Therapeutics
Aug 03We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now
Jun 09Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease
May 03Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)
Mar 13Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year
Mar 10Regulus Therapeutics announces closing of $19.4M private placement
Dec 08Regulus Therapeutics EPS beats by $0.17, beats on revenue
Nov 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$42m |
| Jun 30 2024 | n/a | n/a | -US$35m |
| Mar 31 2024 | n/a | n/a | -US$31m |
| Dec 31 2023 | US$3m | US$616k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$29m |
| Jun 30 2023 | n/a | n/a | -US$28m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$1m | US$598k | -US$28m |
| Sep 30 2022 | n/a | n/a | -US$29m |
| Jun 30 2022 | n/a | n/a | -US$30m |
| Mar 31 2022 | n/a | n/a | -US$29m |
| Dec 31 2021 | US$2m | US$568k | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$22m |
| Jun 30 2021 | n/a | n/a | -US$15m |
| Mar 31 2021 | n/a | n/a | -US$16m |
| Dec 31 2020 | US$2m | US$552k | -US$16m |
| Sep 30 2020 | n/a | n/a | -US$19m |
| Jun 30 2020 | n/a | n/a | -US$23m |
| Mar 31 2020 | n/a | n/a | -US$21m |
| Dec 31 2019 | US$2m | US$536k | -US$19m |
| Sep 30 2019 | n/a | n/a | -US$22m |
| Jun 30 2019 | n/a | n/a | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$36m |
| Dec 31 2018 | US$2m | US$520k | -US$49m |
| Sep 30 2018 | n/a | n/a | -US$55m |
| Jun 30 2018 | n/a | n/a | -US$60m |
| Mar 31 2018 | n/a | n/a | -US$68m |
| Dec 31 2017 | US$2m | US$475k | -US$72m |
Compensation vs Market: Jay's total compensation ($USD2.57M) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: Jay's compensation has increased whilst the company is unprofitable.
CEO
Jay Hagan (55 yo)
7.5yrs
Tenure
US$2,574,323
Compensation
Mr. Joseph P. Hagan, also known as Jay, served as Independent Director of Zosano Pharma Corporation since May 22, 2015, until May 10, 2022. He has been the Chief Executive Officer and Director of Regulus T...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.5yrs | US$2.57m | 0.087% $ 80.0k | |
| Chief Financial Officer | 5.3yrs | US$1.07m | 0.0088% $ 8.1k | |
| Senior VP | 13.8yrs | US$1.09m | 0.015% $ 14.1k | |
| President | 1.4yrs | no data | 0% $ 0 | |
| VP of Finance & Controller | 5.3yrs | no data | no data | |
| Senior Vice President of Clinical Operations | 2yrs | no data | no data | |
| Chief Medical Officer | 2yrs | no data | no data | |
| Vice President of Translational Medicine | no data | no data | no data |
5.3yrs
Average Tenure
55yo
Average Age
Experienced Management: RGLS's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.5yrs | US$2.57m | 0.087% $ 80.0k | |
| President | 1.4yrs | no data | 0% $ 0 | |
| Independent Director | 11.6yrs | US$99.44k | 0.060% $ 54.7k | |
| Member of the Scientific Advisory Board | 5.7yrs | US$1.48m | no data | |
| Independent Chairman of the Board | 15.8yrs | US$131.44k | 1.49% $ 1.4m | |
| Chairman of the Scientific Advisory Board & Independent Director | 15.8yrs | US$95.44k | 0.0039% $ 3.6k | |
| Independent Director | 5.4yrs | US$97.44k | 0% $ 0 | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 8.4yrs | US$93.44k | 0.0027% $ 2.5k | |
| Independent Director | 6.6yrs | US$107.44k | 0.010% $ 9.4k | |
| Independent Director | 7.4yrs | US$93.44k | 0.0072% $ 6.6k |
7.5yrs
Average Tenure
61yo
Average Age
Experienced Board: RGLS's board of directors are considered experienced (7.5 years average tenure).